KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLong-Term Debt RepaymentsR&D In ProcessShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Pfizer (PFE) Short-Term Debt issuances (2016 - 2025)

Historic Short-Term Debt issuances for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $6.0 million.

  • Pfizer's Short-Term Debt issuances fell 9992.66% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 billion, marking a year-over-year decrease of 6132.84%. This contributed to the annual value of $8.9 billion for FY2024, which is 9683.98% up from last year.
  • Pfizer's Short-Term Debt issuances amounted to $6.0 million in Q3 2025, which was down 9992.66% from -$517.0 million recorded in Q2 2025.
  • Pfizer's 5-year Short-Term Debt issuances high stood at $8.2 billion for Q3 2024, and its period low was -$2.0 billion during Q1 2024.
  • Its 5-year average for Short-Term Debt issuances is $1.6 billion, with a median of -$9.5 million in 2021.
  • The largest annual percentage gain for Pfizer's Short-Term Debt issuances in the last 5 years was 648671.88% (2024), contrasted with its biggest fall of 100221.24% (2024).
  • Pfizer's Short-Term Debt issuances (Quarter) stood at $265.0 million in 2021, then surged by 1366.79% to $3.9 billion in 2022, then grew by 19.14% to $4.6 billion in 2023, then skyrocketed by 76.53% to $8.2 billion in 2024, then plummeted by 99.93% to $6.0 million in 2025.
  • Its last three reported values are $6.0 million in Q3 2025, -$517.0 million for Q2 2025, and -$386.0 million during Q1 2025.